HLS THERAPEUTICS INC (HLS.CA) Stock Fundamental Analysis
TSX:HLS - Toronto Stock Exchange - CA40390B1094 - Common Stock - Currency: CAD
Taking everything into account, HLS scores 3 out of 10 in our fundamental rating. HLS was compared to 35 industry peers in the Pharmaceuticals industry. The financial health of HLS is average, but there are quite some concerns on its profitability. HLS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HLS has reported negative net income.
In the past year HLS had a positive cash flow from operations.
HLS had negative earnings in each of the past 5 years.
In the past 5 years HLS always reported a positive cash flow from operatings.
1.2 Ratios
HLS has a Return On Assets (-11.68%) which is in line with its industry peers.
The Return On Equity of HLS (-26.92%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.68% | ||
| ROE | -26.92% | ||
| ROIC | N/A |
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of HLS (83.05%) is better than 100.00% of its industry peers.
HLS's Gross Margin has declined in the last couple of years.
HLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.05% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
2. Health
2.1 Basic Checks
HLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HLS has been reduced compared to 1 year ago.
HLS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HLS has been reduced compared to a year ago.
2.2 Solvency
HLS has an Altman-Z score of -0.75. This is a bad value and indicates that HLS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of HLS (-0.75) is comparable to the rest of the industry.
HLS has a debt to FCF ratio of 5.94. This is a neutral value as HLS would need 5.94 years to pay back of all of its debts.
HLS's Debt to FCF ratio of 5.94 is fine compared to the rest of the industry. HLS outperforms 77.14% of its industry peers.
A Debt/Equity ratio of 0.87 indicates that HLS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.87, HLS is not doing good in the industry: 74.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | 5.94 | ||
| Altman-Z | -0.75 |
ROIC/WACCN/A
WACC8.31%
2.3 Liquidity
HLS has a Current Ratio of 1.43. This is a normal value and indicates that HLS is financially healthy and should not expect problems in meeting its short term obligations.
HLS has a Current ratio (1.43) which is in line with its industry peers.
HLS has a Quick Ratio of 1.12. This is a normal value and indicates that HLS is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.12, HLS perfoms like the industry average, outperforming 48.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
HLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.72%, which is quite impressive.
HLS shows a decrease in Revenue. In the last year, the revenue decreased by -6.62%.
Measured over the past years, HLS shows a small growth in Revenue. The Revenue has been growing by 0.88% on average per year.
EPS 1Y (TTM)33.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)-6.62%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%1.2%
3.2 Future
The Earnings Per Share is expected to grow by 22.85% on average over the next years. This is a very strong growth
Based on estimates for the next years, HLS will show a small growth in Revenue. The Revenue will grow by 7.26% on average per year.
EPS Next Y52.22%
EPS Next 2Y28.76%
EPS Next 3Y21.38%
EPS Next 5Y22.85%
Revenue Next Year1.06%
Revenue Next 2Y5.86%
Revenue Next 3Y9.83%
Revenue Next 5Y7.26%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
HLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HLS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HLS is valued a bit cheaper than 65.71% of the companies in the same industry.
82.86% of the companies in the same industry are more expensive than HLS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.48 | ||
| EV/EBITDA | 11.21 |
4.3 Compensation for Growth
A more expensive valuation may be justified as HLS's earnings are expected to grow with 21.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.76%
EPS Next 3Y21.38%
5. Dividend
5.1 Amount
HLS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:HLS (7/16/2025, 7:00:00 PM)
4.89
-0.01 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.35%
Inst Owner ChangeN/A
Ins Owners0.52%
Ins Owner ChangeN/A
Market Cap154.33M
Analysts75.56
Price Target5.74 (17.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.42%
Min EPS beat(2)-16.97%
Max EPS beat(2)-11.88%
EPS beat(4)1
Avg EPS beat(4)-7.57%
Min EPS beat(4)-16.97%
Max EPS beat(4)0.99%
EPS beat(8)1
Avg EPS beat(8)-44.71%
EPS beat(12)1
Avg EPS beat(12)-55.96%
EPS beat(16)3
Avg EPS beat(16)-37.92%
Revenue beat(2)0
Avg Revenue beat(2)-1.08%
Min Revenue beat(2)-1.99%
Max Revenue beat(2)-0.17%
Revenue beat(4)1
Avg Revenue beat(4)-1.96%
Min Revenue beat(4)-5.77%
Max Revenue beat(4)0.1%
Revenue beat(8)2
Avg Revenue beat(8)-3.43%
Revenue beat(12)2
Avg Revenue beat(12)-4.67%
Revenue beat(16)3
Avg Revenue beat(16)-4.8%
PT rev (1m)0%
PT rev (3m)-8.54%
EPS NQ rev (1m)-1.45%
EPS NQ rev (3m)-1.45%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.15%
Revenue NQ rev (1m)-1.09%
Revenue NQ rev (3m)-1.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.98 | ||
| P/FCF | 10.48 | ||
| P/OCF | 10.44 | ||
| P/B | 1.68 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.21 |
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)0.47
FCFY9.55%
OCF(TTM)0.47
OCFY9.58%
SpS2.47
BVpS2.9
TBVpS-2.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.68% | ||
| ROE | -26.92% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.05% | ||
| FCFM | 18.91% |
ROA(3y)-11.74%
ROA(5y)-9%
ROE(3y)-24.86%
ROE(5y)-18.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-2.67%
F-Score6
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | 5.94 | ||
| Debt/EBITDA | 4.11 | ||
| Cap/Depr | 0.15% | ||
| Cap/Sales | 0.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 76.2% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | -0.75 |
F-Score6
WACC8.31%
ROIC/WACCN/A
Cap/Depr(3y)0.36%
Cap/Depr(5y)20.34%
Cap/Sales(3y)0.19%
Cap/Sales(5y)11.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y52.22%
EPS Next 2Y28.76%
EPS Next 3Y21.38%
EPS Next 5Y22.85%
Revenue 1Y (TTM)-6.62%
Revenue growth 3Y-1.91%
Revenue growth 5Y0.88%
Sales Q2Q%1.2%
Revenue Next Year1.06%
Revenue Next 2Y5.86%
Revenue Next 3Y9.83%
Revenue Next 5Y7.26%
EBIT growth 1Y35.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year287.73%
EBIT Next 3Y66.38%
EBIT Next 5Y41.74%
FCF growth 1Y-28.87%
FCF growth 3Y-20.24%
FCF growth 5Y-19.65%
OCF growth 1Y-29.16%
OCF growth 3Y-21.32%
OCF growth 5Y-21.24%